Angitia Biopharmaceuticals, a Woodland Hills, CA-based biotech focused on serious musculoskeletal diseases, raised $120M in Series C funding.
The round was led by Bain Capital Life Sciences with participation from Janus Henderson and OrbiMed, 3H Health Investment, Yonghua Capital, Legend Capital, and Elikon Venture.
In conjunction with the financing, Dr. Norbert Riedel, Ph.D., will join the Company’s Board of Directors.
The company intends to use the funds to support development of its pipeline of novel, differentiated treatments, including AGA2118, AGA2115, AGA111 and other pipeline assets for the treatment of serious musculoskeletal diseases.
Led by CEO Dr. David Ke, Angitia Biopharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases. It is currently studying 3 biologic product candidates in the clinic for the treatment of osteoporosis, osteogenesis imperfecta (OI), and spinal fusion.
Angitia is advancing AGA2118 and AGA2115, bispecific antibodies targeting sclerostin and DKK1, through clinical development for osteoporosis and osteogenesis imperfecta (OI), respectively. The two molecules represent the next generation of dual-acting treatments for skeletal disease, increasing bone formation and decreasing bone resorption. With these two bispecifics, Angitia seeks to promote stronger, more organized skeletal development in patients. The company is also developing AGA111, a biologic to promote spinal fusion in patients with degenerative disc disease.
FinSMEs
11/12/2024